DB 1314
Alternative Names: DB-1314Latest Information Update: 17 Dec 2024
Price :
$50 *
At a glance
- Originator Duality Biologics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunotoxins
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 23 Oct 2024 Safety and pharmacodynamics data from preclinical trials in Solid tumours presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR Symposium-2024)
- 02 Sep 2024 DB 1314 is available for licensing as of 02 Sep 2024. https://www.dualitybiologics.com/partnership.html
- 14 Aug 2024 Preclinical trials in Solid tumours in China (Parenteral), prior to August 2024